JP2024533990A - Ｂｒｍの調節に使用するためのフェノール誘導体 - Google Patents
Ｂｒｍの調節に使用するためのフェノール誘導体 Download PDFInfo
- Publication number
- JP2024533990A JP2024533990A JP2024507995A JP2024507995A JP2024533990A JP 2024533990 A JP2024533990 A JP 2024533990A JP 2024507995 A JP2024507995 A JP 2024507995A JP 2024507995 A JP2024507995 A JP 2024507995A JP 2024533990 A JP2024533990 A JP 2024533990A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- compound
- pharma
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231220P | 2021-08-09 | 2021-08-09 | |
| US202163231219P | 2021-08-09 | 2021-08-09 | |
| US63/231,219 | 2021-08-09 | ||
| US63/231,220 | 2021-08-09 | ||
| PCT/US2022/039696 WO2023018648A1 (en) | 2021-08-09 | 2022-08-08 | Phenol derivatives for use in the modulation of brm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533990A true JP2024533990A (ja) | 2024-09-18 |
| JP2024533990A5 JP2024533990A5 (enExample) | 2025-08-18 |
Family
ID=83149068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507995A Pending JP2024533990A (ja) | 2021-08-09 | 2022-08-08 | Ｂｒｍの調節に使用するためのフェノール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11993599B2 (enExample) |
| EP (1) | EP4384517A1 (enExample) |
| JP (1) | JP2024533990A (enExample) |
| KR (1) | KR20240046498A (enExample) |
| AU (1) | AU2022328137A1 (enExample) |
| CA (1) | CA3225467A1 (enExample) |
| TW (1) | TW202321250A (enExample) |
| WO (1) | WO2023018648A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225467A1 (en) | 2021-08-09 | 2023-02-16 | Genentech, Inc. | Phenol derivatives for use in the modulation of brm |
| EP4540242A1 (en) * | 2022-06-16 | 2025-04-23 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
| WO2024214019A1 (en) | 2023-04-12 | 2024-10-17 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018510851A (ja) * | 2015-02-25 | 2018-04-19 | ジェネンテック， インコーポレイテッド | 治療用ピリダジン化合物およびその使用 |
| WO2020251971A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251974A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| WO2021067606A1 (en) * | 2019-10-01 | 2021-04-08 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| WO2021083949A1 (en) * | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
| JP2023535409A (ja) * | 2020-07-21 | 2023-08-17 | ジェネンテック， インコーポレイテッド | Ｂｒｍ分解の抗体コンジュゲート化化学的誘導物質及びｂｒｍ分解の方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207538A1 (en) | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
| EP3787747A4 (en) | 2018-04-30 | 2022-01-12 | Dana-Farber Cancer Institute, Inc. | POLYBROMO-1 (PBRM1) SMALL MOLECULE DEGRADATION PRODUCTS |
| EP3817822A4 (en) * | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020078933A1 (en) | 2018-10-16 | 2020-04-23 | Boehringer Ingelheim International Gmbh | Proteolysis targeting chimera (protacs) as degraders of smarca2 and/or smarca4 |
| FR3090393B1 (fr) | 2018-12-20 | 2021-04-23 | Ifp Energies Now | Procédé de traitement d’une charge alcool pour la production d’oléfines |
| WO2020172655A1 (en) | 2019-02-23 | 2020-08-27 | New York University | Photoswitchable protacs and synthesis and uses thereof |
| WO2020251969A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| BR112022004573A2 (pt) | 2019-09-12 | 2022-06-07 | Aurigene Discovery Tech Ltd | Método para identificar respondedores para degradadores de smarca2/4 |
| EP4054724A4 (en) | 2019-10-28 | 2023-12-27 | C4 Therapeutics, Inc. | BIFUNCTIONAL CONNECTIONS |
| JP7706456B2 (ja) | 2020-01-10 | 2025-07-11 | アムジエン・インコーポレーテツド | Ｓｍａｒｃａ２－ｖｈｌ分解剤 |
| EP4132529A4 (en) | 2020-04-06 | 2024-05-01 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| JP2023529908A (ja) * | 2020-06-09 | 2023-07-12 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| WO2022109396A1 (en) | 2020-11-20 | 2022-05-27 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2022183056A1 (en) | 2021-02-26 | 2022-09-01 | Salk Institute For Biological Studies | Modulating regulatory t cell function in autoimmune disease and cancer |
| CA3225467A1 (en) | 2021-08-09 | 2023-02-16 | Genentech, Inc. | Phenol derivatives for use in the modulation of brm |
-
2022
- 2022-08-08 CA CA3225467A patent/CA3225467A1/en active Pending
- 2022-08-08 WO PCT/US2022/039696 patent/WO2023018648A1/en not_active Ceased
- 2022-08-08 KR KR1020247004828A patent/KR20240046498A/ko active Pending
- 2022-08-08 US US17/883,004 patent/US11993599B2/en active Active
- 2022-08-08 AU AU2022328137A patent/AU2022328137A1/en active Pending
- 2022-08-08 JP JP2024507995A patent/JP2024533990A/ja active Pending
- 2022-08-08 EP EP22761812.1A patent/EP4384517A1/en active Pending
- 2022-08-09 TW TW111129895A patent/TW202321250A/zh unknown
-
2024
- 2024-03-13 US US18/604,314 patent/US12428419B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018510851A (ja) * | 2015-02-25 | 2018-04-19 | ジェネンテック， インコーポレイテッド | 治療用ピリダジン化合物およびその使用 |
| WO2020251971A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251974A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| WO2021067606A1 (en) * | 2019-10-01 | 2021-04-08 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| WO2021083949A1 (en) * | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
| JP2023535409A (ja) * | 2020-07-21 | 2023-08-17 | ジェネンテック， インコーポレイテッド | Ｂｒｍ分解の抗体コンジュゲート化化学的誘導物質及びｂｒｍ分解の方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4384517A1 (en) | 2024-06-19 |
| KR20240046498A (ko) | 2024-04-09 |
| US12428419B2 (en) | 2025-09-30 |
| WO2023018648A1 (en) | 2023-02-16 |
| AU2022328137A1 (en) | 2024-02-01 |
| US20240383897A1 (en) | 2024-11-21 |
| US20230112485A1 (en) | 2023-04-13 |
| TW202321250A (zh) | 2023-06-01 |
| US11993599B2 (en) | 2024-05-28 |
| CA3225467A1 (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7603609B2 (ja) | アンドロゲン受容体を標的に分解する二官能性キメラ複素環式化合物及びその使用 | |
| ES2829636T3 (es) | Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso | |
| AU2015261812B2 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors | |
| US10450296B2 (en) | Heterocyclic compounds useful as Pim kinase inhibitors | |
| WO2023066350A1 (zh) | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 | |
| US12428419B2 (en) | Therapeutic compounds | |
| CA2889526C (en) | 2-aminopyridine compounds | |
| AU2017279027A1 (en) | Chemical Compounds | |
| EA019785B1 (ru) | Бензофуропиримидиноны в качестве ингибиторов протеинкиназ, фармацевтические композиции, их содержащие, и их применение | |
| WO2022003575A1 (en) | Her2 mutation inhibitors | |
| JP2019503357A (ja) | ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体 | |
| EP4351558A1 (en) | Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes | |
| JP2011507824A (ja) | アンドロゲン受容体関連状態の治療に使用の二環系誘導体 | |
| JP7511097B1 (ja) | Ｈｅｒ２変異阻害薬 | |
| US12226414B2 (en) | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof | |
| RU2683940C1 (ru) | Производные имидазотиазола в качестве модуляторов активности tnf | |
| KR20210083287A (ko) | 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체 | |
| US20250051344A1 (en) | Bifunctional selective degraders of smarca2 and therapeutic uses thereof | |
| CN117794933A (zh) | 用于调节brm的酚衍生物 | |
| HK40111551A (zh) | 用於调节brm的酚衍生物 | |
| JP2024089651A (ja) | Ｈｅｒ２変異阻害薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250807 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250807 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260414 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260421 |